Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.
Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.
